|Bid||24.77 x 1300|
|Ask||25.19 x 800|
|Day's Range||23.30 - 25.87|
|52 Week Range||3.76 - 32.69|
|Beta (5Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA Pharma, will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference, taking place virtually April 20-21, 2021. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Additional Preclinical Data Presented at AACR 2021 On April 10, 2021, ESSA Pharma, Inc. (NASDAQ:EPIX) announced the presentation of encouraging preclinical data at the 2021 American Association of Cancer Research (AACR) annual meeting. A copy of the presentation can be found here . The data presented by ESSA builds
ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits high potency, low metabolism and on-target specificity.